Les immunoscintigraphies en oncologie

Vuillez, Jean‐Philippe

doi:10.1016/0248-8663(96)80798-3

Cited by 3 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunoscintigraphy is a diagnostic imaging technique where a radiolabeled tracer is administered to a patient, usually intravenously, and the body is then scanned for radioactive emissions to provide information about the presence and nature of lesions [ 80 , 81 ]. Tracers typically consist of an antibody probe specific to a certain molecular (disease) target, coupled to a β- or γ-emitting radionuclide [ 81 , 82 ].…”

Section: Use Of Radiolabeled Nanobodiesmentioning

confidence: 99%

Targeted Alpha Therapy (TAT) with Single-Domain Antibodies (Nanobodies)

Hurley

Cao

Huang³

et al. 2023

Cancers

View full text Add to dashboard Cite

The persistent threat of cancer necessitates the development of improved and more efficient therapeutic strategies that limit damage to healthy tissues. Targeted alpha therapy (TαT), a novel form of radioimmuno-therapy (RIT), utilizes a targeting vehicle, commonly antibodies, to deliver high-energy, but short-range, alpha-emitting particles specifically to cancer cells, thereby reducing toxicity to surrounding normal tissues. Although full-length antibodies are often employed as targeting vehicles for TαT, their high molecular weight and the presence of an Fc-region lead to a long blood half-life, increased bone marrow toxicity, and accumulation in other tissues such as the kidney, liver, and spleen. The discovery of single-domain antibodies (sdAbs), or nanobodies, naturally occurring in camelids and sharks, has introduced a novel antigen-specific vehicle for molecular imaging and TαT. Given that nanobodies are the smallest naturally occurring antigen-binding fragments, they exhibit shorter relative blood half-lives, enhanced tumor uptake, and equivalent or superior binding affinity and specificity. Nanobody technology could provide a viable solution for the off-target toxicity observed with full-length antibody-based TαT. Notably, the pharmacokinetic properties of nanobodies align better with the decay characteristics of many short-lived α-emitting radionuclides. This review aims to encapsulate recent advancements in the use of nanobodies as a vehicle for TαT.

show abstract